Beijing Wantai Biological Pharmacy Enterprise Co Ltd
603392.SS · Health Technology · Biotechnology · CN
4,016 employees · ystwt.com
About
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. generates revenue through the research, development, production, and sale of in vitro diagnostic reagents and equipment, as well as vaccines. The company sells ELISA reagents, chemiluminescence reagents, biochemical reagents, quality control products, and automatic chemiluminescence immunoassay analyzers. It also markets the Hecolin vaccine for hepatitis E and distributes agent products from Bio-Rad Laboratories Inc and Diagast SAS, including in-vitro diagnostics and equipment. Customers include healthcare institutions and laboratories requiring diagnostic solutions and vaccine services. The firm's primary revenue streams come from its own diagnostic reagents and equipment, with Hecolin as a key vaccine product. Bio-Rad Laboratories Inc and Diagast SAS are the specific brands whose products are sold as agents. Healthcare providers and diagnostic laboratories form the main customer segments purchasing these products for medical testing and prevention. Beijing Wantai's business model relies on both direct sales of its proprietary products and the distribution of third-party agent products. The company focuses on in-vitro diagnostic solutions and hepatitis E vaccines, targeting healthcare facilities and laboratories that require reliable testing tools and preventive healthcare services.
Annual results
Reported figures, CNY · revenue down 19.0% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 1.8B | -398M | -21.9% | — |
| 2024 | 2.2B | 106M | 4.7% | — |
| 2023 | 5.5B | 1.2B | 22.6% | — |
| 2022 | 11.2B | 4.7B | 42.3% | — |
| 2021 | 5.8B | 2.0B | 35.1% | — |
Dividends per share
603392.SS in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Beijing Wantai Biological Pharmacy Enterprise Co Ltd are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.